Wu Z, Zhu L, Mai J, Shen H,Xu R. Rad51 Silencing with siRNA delivered by porous silicon-based microparticle enhances the anti-cancer effect of doxorubicin in triple-negative breast cancer. J Biomed Nanotechnol. 2021 Dec 1;17(12):2351-2363.
He W, Qin M, Cai Y, Gao X, Cao S, Wang Z, Chen H*,Xu R*. Downregulation of HOXC6 by miR-27a ameliorates gefitinib resistance in non-small cell lung cancer. Am J Cancer Res. 2021 Sep 15;11(9):4329-4346.
Ming JX, Wang ZC, Huang Y, Ohishi H, Wu RJ, Shao Y, Wang H, Qin MY, Wu ZL, Li YY, Chang Zhou S, Chen H, Liu H,Xu R. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. J Ethnopharmacol. 2021 Jan 30;265:113302.
Wu ZL, Zhao J,Xu R. Recent advances in oral nano-antibiotics for bacterial infection therapy. Int J Nanomedicine. 2020 Dec 1;15:9587-9610.
Cao S, Wang Z, Gao X, He W, Cai Y, Chen H*,Xu R*. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res. 2018 Sep 6;37(1):220.
Tang Y#, Li Y#,Xu R#, Li S, Hu H, Xiao C, Wu H, Zhu L, Ming J, Chu Z, Xu H, Yang X, Li Z. Self-assembly of folic acid dextran conjugates for cancer chemotherapy. Nanoscale. 2018 Sep 20;10(36):17265-17274.
Mei C, Zhou S, Zhu L, Ming J, Zeng F,Xu R. Antitumor effects of laminaria extract fucoxanthin on lung cancer. Mar Drugs. 2017 Feb 15;15(2). pii: E39.
Xu R#, Zhang G#, Mai J#, Deng X#, Segura-Ibarra V, Wu S, Shen J, Liu H, Hu Z, Chen L, Huang Y, Koay E, Huang Y, Liu J, Ensor JE, Blanco E, Liu X, Ferrari M, Shen H. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat Biotechnol. 2016 Apr;34(4):414-8.
Shen J#,Xu R#, Mai J#, Kim HC, Guo X, Qin G, Yang Y, Wolfram J, Mu C, Xia X, Gu J, Liu X, Mao ZW, Ferrari M, Shen H. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano. 2013 Nov 26;7(11):9867-80.
Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small. 2013 May 27;9(9-10):1799-808.